NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Thursday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Up 0.4 %

Shares of NASDAQ:NURO opened at $4.02 on Thursday. The business’s 50 day moving average is $4.02 and its 200 day moving average is $3.88. The stock has a market cap of $8.20 million, a P/E ratio of -0.87 and a beta of 2.20. NeuroMetrix has a 52-week low of $2.66 and a 52-week high of $4.73.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings results on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. The firm had revenue of $0.59 million for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. During the same quarter last year, the firm earned ($1.66) earnings per share.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.